Recro Pharma Inc (REPH) Receives Average Recommendation of “Buy” from Brokerages
Shares of Recro Pharma Inc (NASDAQ:REPH) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $13.50.
Several research analysts have commented on REPH shares. Zacks Investment Research downgraded Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. Piper Jaffray Companies restated a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a report on Friday, October 27th. Finally, Oppenheimer started coverage on Recro Pharma in a report on Tuesday. They set a “buy” rating and a $19.00 price objective on the stock.
In other news, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $9.50, for a total value of $973,180.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of Recro Pharma stock in a transaction on Friday, December 29th. The shares were sold at an average price of $9.27, for a total value of $169,001.37. The disclosure for this sale can be found here. Insiders sold a total of 860,414 shares of company stock worth $8,289,916 over the last quarter. Company insiders own 21.60% of the company’s stock.
Shares of Recro Pharma (NASDAQ:REPH) traded up $0.12 during mid-day trading on Tuesday, hitting $8.21. The company had a trading volume of 47,792 shares, compared to its average volume of 114,843. The company has a market cap of $157.01, a price-to-earnings ratio of -3.82 and a beta of -0.60. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $10.59. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/13/recro-pharma-inc-reph-receives-average-recommendation-of-buy-from-brokerages.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.